1. Pfizer finds COVID-19 drug candidate, plots summer testing — Myokardia at inflection point as heart drug readout nears — Mylan prepares hydroxychloroquine giveaways after production ramp-up — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Fascinating

Discussion in 'Medacta' started by anonymous, Jun 27, 2019 at 10:41 AM.

  1. anonymous

    anonymous Guest

    I just find it fascinating that Medacta is able to seemingly walk into a new territory and ‘instantly convert’ some of the largest volume surgeons. Many of these Dr’s have been with the same company for 10+ years, I know of a few that were even tied to their respective companies as clinicians. Then you toss in the week long trips to Switzerland to visit their headquarters... You would think this would be an investigative journalists wet dream. Close surgeon friend of mine told me about an office meeting with one of the local Medacta reps and their manager and they were fairly open about naming him as a ‘proctor’ and financially enticing him to switch.
     
  2. Yeah you're doing so much for and are such close friends with your surgeon that he's taking meetings with other companies. Oh wait, you owe him your entire livelihood and provide him with little-to-zero in return... the explanation for losing big surgeons can't possibly be that the large ortho companies stopped innovating, massively dialed back research funding and education and became just a marketing machine decades ago, could it?

    What you're saying about Medacta is the same thing people said about Biomet fast forward 30/40 years... Zimmer had to buy Biomet for $12 billion to stop the bleeding

     
  3. anonymous

    anonymous Guest

    What is even more fascinating is how Medacta pays surgeons. Train a "key" surgeon on their products, and turn them into a visiting surgeon site. Surgeons are funneled to this key surgeon who trains and "sells' them on the Medacta product. Surgeons return home and when they start using Medacta, a portion of the sales goes back into the "key surgeons" pockets. Explain to me how that is legal. Money coming right out of Switzerland, sounds extremely shady to me. Im sure the Department of Justice would be interested enough to take a look.
     
  4. anonymous

    anonymous Guest

    Surgeon peer to peer education used to be a strong point of your big box ortho company too... the strikers, zimmers and depuys of the world just decided to stop spending the time/money on teaching because they no longer need to. Prevailing wisdom is your market share is "locked up" via marketing fellowship/resident product exposure -truth of the situation- you big company idiots are finding out that your business isnt locked up - let's face it striker is growing because of the acquired mako tv cart unit they didnt invent

    Cry me a river. The DOJ can't save your job